Opioid Induced Constipation News and Research

RSS
Top-line data from S.L.A. Pharma’s Nalcol Phase 2 study on OIC

Top-line data from S.L.A. Pharma’s Nalcol Phase 2 study on OIC

Salix first quarter total product revenue increases 62% to $171.1M

Salix first quarter total product revenue increases 62% to $171.1M

Methylnaltrexone may restore bowel function in critically ill patients

Methylnaltrexone may restore bowel function in critically ill patients

Salix third quarter total product revenue increases 81% to $146.2 million

Salix third quarter total product revenue increases 81% to $146.2 million

Cubist signs definitive agreement to acquire Adolor

Cubist signs definitive agreement to acquire Adolor

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation

Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics third quarter net loss increases to $17.1 million

Progenics third quarter net loss increases to $17.1 million

Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC

Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC

FDA, EMA and Health Canada approve Progenics' RELISTOR in pre-filled syringes

FDA, EMA and Health Canada approve Progenics' RELISTOR in pre-filled syringes

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.